



## BMT CTN 0303

### T cell Depleted PBSCT for AML

#### Objective

- Assess disease-free survival at 6 months post transplant

#### Eligibility

- AML in CR1, CR2 or therapy-related AML
- 6/6 HLA matched sibling who is willing to undergo G-CSF mobilization
- Age 18-65 years

### TREATMENT SCHEMA

#### Donor

G-CSF 16  $\mu\text{g}/\text{kg}/\text{d}$  SQ starting Day -5, continue until final day of collection

CD34<sup>+</sup> target:  
> 5 x 10<sup>6</sup>/kg rec weight

Collect on Day -1,  
continue if needed on Day 0 and Day 1

CD3<sup>+</sup> target:  
< 1.0 x 10<sup>5</sup>/kg rec weight

#### Patient

- TBI (Day -9, -8, -7, -6) Total dose=1375 cGy
- Thiotepa (Day -5, -4)
- CY (Day -3, -2)
- Rabbit ATG (Day -4)  
\*(no additional GVHD prophylaxis)

HCT within  
48-72 hours from last dose of regimen

To view the entire protocol, go to <http://www.bmtctn.net>  
or the PDQ website at <http://cancer.gov/clinicaltrials/BMTCTN-0303>

This is a Phase II multi-center trial jointly sponsored by the NHLBI and NCI.